Pharmaceutical compounds able to modulate vesicle trafficking may be a possible therapeutic option for PD treatment as recently suggested by the ability of Levetiracetam to rescue the LRRK2 G2019S pathological effect [48]. Here, LRRK2 is linked to Parkinson disease.